China,

February 2020

This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously anticipating the challenges and opportunities on the horizon in the new decade. From the steady national expansion of pilot regulatory reforms to the continuing exuberance of enterprising biotechs to the bold multidimensionality of multinationals’ investment in China, the report serves to recap the noteworthy advancements and positive trajectory of the Chinese healthcare sector even as the country pulls together to deal with the ongoing coronavirus crisis.

China has dominated the global healthcare story in both positive and negative ways over the past years and what is clear is that global scrutiny and attention will continue in the future. Over the past year, as over 160 industry leaders and executives working in China have shared their insights and experiences on the ground, their sense of purpose, their sheer enthusiasm and their tireless energy have been truly striking. It is clear that there is no industry and no country more exciting to …

Articles

China’s Role in Defeating Antimicrobial Resistance

According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the biggest threats to global health, food security, and development today. If this trend is not slowed or reversed, it could jeopardize many, if not most, of our medical advancements to date. Antimicrobials are essential for the prevention and treatment of infections, which affect…

Chinese Biotech Strategies: Biologics or Small Molecules

While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent a stunning eight out of the top ten best-selling drugs in 2019. In China, this sector has lagged behind developed markets. However, despite being a…

Pharma Faces: Shirley Xu, Baxter China

The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market has been left playing catch-up. As the Chinese government looks to streamline its regulatory approval processes, MNCs plan to expand their commercial operations in China,…

Company Spotlight: HiNounou – Gamifying Preventative in China

As patients and consumers grow more educated and proactive in managing their own health and wellbeing, new ventures are hoping to serve their needs in not just prophylactic but also preventative health. HiNounou is a nifty little start-up based in Shanghai seeking to redefine the health management app. Health is the result of a…